Glycemic Holter Study (Continuous Glucose Monitoring) - (OPTIMA)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Vildagliptin
Sitagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes mellitus, vildagliptin, continuous glucose monitoring
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetes Mellitus (DM) willing to perform SMBG at least 6 times daily to use the MiniMed CGMS for up to 3 consecutive days on 2 occasions.
- HbA1c: 6.5 to 9% with metformin monotherapy for a least 3 months
Exclusion Criteria:
- Age >= 80 years
- BMI <= 22 and >=40 kg/m2
- Secondary T2 DM
- Hepatic failure, ASAT/ALAT>3 ULN, and moderate/severe renal failure (CI < 50 ml/min) CHF III & IV
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Vildagliptin
Sitagliptin
Arm Description
Outcomes
Primary Outcome Measures
Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion)
Secondary Outcome Measures
Glycemic control assessed through CSGM
Glycemic control assessed by A1C, FPG, PPG and the mean of 6 points self-monitoring of blood glucose (SMBG) at baseline and after 8 weeks
Unrecognized hypoglycemic periods recorded by CSGM, frequency and duration
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01193296
Brief Title
Glycemic Holter Study (Continuous Glucose Monitoring) -
Acronym
OPTIMA
Official Title
Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and After an 8-week Period With the Addition of Either Vildagliptin or Sitagliptin in Patients Insufficiently Controlled by Metformin After at Least 3 Months of Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
June 2010 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Diabetes mellitus, vildagliptin, continuous glucose monitoring
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vildagliptin
Arm Type
Experimental
Arm Title
Sitagliptin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Primary Outcome Measure Information:
Title
Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion)
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Glycemic control assessed through CSGM
Time Frame
8 weeks
Title
Glycemic control assessed by A1C, FPG, PPG and the mean of 6 points self-monitoring of blood glucose (SMBG) at baseline and after 8 weeks
Time Frame
8 weeks
Title
Unrecognized hypoglycemic periods recorded by CSGM, frequency and duration
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 Diabetes Mellitus (DM) willing to perform SMBG at least 6 times daily to use the MiniMed CGMS for up to 3 consecutive days on 2 occasions.
HbA1c: 6.5 to 9% with metformin monotherapy for a least 3 months
Exclusion Criteria:
Age >= 80 years
BMI <= 22 and >=40 kg/m2
Secondary T2 DM
Hepatic failure, ASAT/ALAT>3 ULN, and moderate/severe renal failure (CI < 50 ml/min) CHF III & IV
Other protocol-defined inclusion/exclusion criteria may apply
Facility Information:
Facility Name
Investigative Site
City
Bondy
Country
France
Facility Name
Investigative Site
City
Corbeil
Country
France
Facility Name
Investigative Site
City
Marseille
Country
France
Facility Name
Investigative Site
City
Nancy
Country
France
Facility Name
Investigative Site
City
Paris
Country
France
Facility Name
Investigative Site
City
Toulouse
Country
France
Facility Name
Investigative Site
City
Venissieux
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
22809630
Citation
Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quere S, Dejager S. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012 Oct;38(4):359-66. doi: 10.1016/j.diabet.2012.06.001. Epub 2012 Jul 17.
Results Reference
derived
PubMed Identifier
22775317
Citation
Monnier L, Colette C, Comenducci A, Vallee D, Dejager S. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther. 2012 Oct;14(10):943-50. doi: 10.1089/dia.2012.0045. Epub 2012 Jul 9.
Results Reference
derived
Learn more about this trial
Glycemic Holter Study (Continuous Glucose Monitoring) -
We'll reach out to this number within 24 hrs